Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
For the treatment of hepatitis C virus (HCV) infection.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.